BACKGROUND Clinical practice guidelines focusing on age-related adjuvant chemotherapy for rectal cancer are currently limited. The present study aimed to explore the impact of age on the efficacy of adjuvant oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy. METHODS We performed a retrospective cohort analysis using data from the Surveillance, E...

CONCLUSION Inhibition of thioredoxin reductase (TrxR) may be a contributing factor in cisplatin-induced ototoxicity. Direct exposure of organ of Corti to cisplatin and oxaliplatin gives equal loss of hair cells. OBJECTIVES Platinum-containing drugs are known to target the anti-oxidant selenoprotein TrxR in cancer cells. Two such anti-cancer, platinum-containing drugs, cisplatin and oxaliplati...

BACKGROUND AND OBJECTIVE Desensitization protocols for patients with immediate hypersensitivity reactions (IHSRs) have proven to be effective, but they are not widely used in clinical practice because of impracticalities such as high cost, long procedure duration, and a lack of trained personnel. We aimed to determine the clinical characteristics of oxaliplatin-induced IHSRs and assess measures...

BACKGROUND The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. METHODS We randomly assigned 2246 patients who had undergone curative resection for stage II o...

The purpose of this study was to clarify the effects of oxaliplatin on the function and expression of the multidrug efflux transporter P-glycoprotein/MDR1 in a porcine kidney epithelial cell line, LLC-PK1, as a renal tubular epithelial model. LLC-PK1 cells were pretreated with or without oxaliplatin for 48 h, and the growth inhibitory effects of a MDR1 substrate, paclitaxel, and the transport o...

Pt compounds still represent the mainstay of the treatment of ovarian carcinoma. The aim of the present study was to investigate the molecular bases of resistance to Pt drugs using an oxaliplatin-resistant ovarian carcinoma cell model IGROV-1/OHP. These cells exhibited high levels of resistance to oxaliplatin, cross-resistance to cisplatin and topotecan and displayed a marked accumulation defec...

The clinical character of oxaliplatin induced thrombocytopenia is marked by severe and acute drop in platelet count associated with bleeding and bruising within a few hours up to 48 hrs after oxaliplatin administration. The nadir of platelet count can be as low value of 2x109/L. The dose intensity of oxaliplatin is associated with an increase in spleen size and both of these aspects correlate w...

The purpose of the review is to consolidate the biological, chemical and therapeutic role of the third generation cytotoxic platinum analogue oxaliplatin [(1R,2R-diamminocyclohexane) oxalatoplatinum(II)] taking the pharmacokinetic and pharmacodynamic data in account. Oxaliplatin is the first derivative of Cisplatin with known therapeutic efficacy for the treatment of colorectal carcinoma. The d...

PURPOSE/OBJECTIVES To review selected recent data pertaining to the use of oxaliplatin in colorectal cancer and its implications for oncology nursing. DATA SOURCES Published articles, abstracts, and conference proceedings. DATA SYNTHESIS Colorectal cancer accounts for about 15% of all new cancers. The search for more effective chemotherapy regimens is ongoing. Oxaliplatin, a member of the d...

PURPOSE Limited data are available regarding the efficacy of hepatic arterial infusion (HAI) of oxaliplatin in patients with liver metastases from colorectal carcinoma (CRC). The aim of the present study was to evaluate the results of HAI of oxaliplatin combined with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with such metastases. METHODS A retrospective analysis of 22 CRC patients...